PMID- 1309848
OWN - NLM
STAT- MEDLINE
DCOM- 19920220
LR  - 20190509
IS  - 0022-1899 (Print)
IS  - 0022-1899 (Linking)
VI  - 165
IP  - 2
DP  - 1992 Feb
TI  - Interleukin-4 inhibits human macrophage activation by tumor necrosis factor, 
      granulocyte-monocyte colony-stimulating factor, and interleukin-3 for 
      antileishmanial activity and oxidative burst capacity.
PG  - 344-51
AB  - Interleukin (IL)-4 has been implicated in the pathogenesis of leishmaniasis in a 
      murine model. Experiments were done to examine the effect of IL-4 on cytokine 
      activation of macrophages. Interferon (IFN)-gamma, granulocyte-macrophage 
      colony-stimulating factor (GM-CSF), tumor necrosis factor-alpha (TNF alpha), and 
      IL-3 activate macrophages to inhibit replication of leishmaniae. IL-4 abrogated 
      in a dose- and time-dependent manner the induction of antileishmanial activity by 
      these cytokines. The depression of oxidative burst capacity is one mechanism by 
      which IL-4 inhibits macrophage activation. IL-4 diminished in a dose- and 
      time-dependent manner the TNF alpha enhancement of oxidative capacity. 
      Pretreatment with IL-4 for 48, 24, or 0 h, respectively, inhibited the generation 
      of superoxide induced by TNF alpha by 90%, 60%, and 40%. Furthermore, IL-4 
      abrogated the enhancement of oxidative capacity by IFN-gamma, GM-CSF, and IL-3. 
      These data suggest that IL-4 is a potent deactivator of macrophage antimicrobial 
      functions and may contribute to the pathogenesis of visceral leishmaniasis.
FAU - Ho, J L
AU  - Ho JL
AD  - Division of International Medicine, Cornell University Medical College, New York, 
      New York 10021.
FAU - He, S H
AU  - He SH
FAU - Rios, M J
AU  - Rios MJ
FAU - Wick, E A
AU  - Wick EA
LA  - eng
GR  - AI-16282/AI/NIAID NIH HHS/United States
GR  - D43-TW00018/TW/FIC NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Infect Dis
JT  - The Journal of infectious diseases
JID - 0413675
RN  - 0 (Cytokines)
RN  - 0 (Interleukin-3)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 11062-77-4 (Superoxides)
RN  - 207137-56-2 (Interleukin-4)
RN  - 82115-62-6 (Interferon-gamma)
RN  - 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)
SB  - IM
MH  - Animals
MH  - Cells, Cultured
MH  - Cytokines/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology
MH  - Humans
MH  - Interferon-gamma/pharmacology
MH  - Interleukin-3/pharmacology
MH  - Interleukin-4/*pharmacology
MH  - Leishmania/*immunology
MH  - Macrophage Activation/*drug effects
MH  - Macrophages/parasitology
MH  - Monocytes/parasitology
MH  - Oxidation-Reduction
MH  - Phagocytosis
MH  - Respiratory Burst/*immunology
MH  - Superoxides/metabolism
MH  - Tumor Necrosis Factor-alpha/pharmacology
EDAT- 1992/02/01 00:00
MHDA- 1992/02/01 00:01
CRDT- 1992/02/01 00:00
PHST- 1992/02/01 00:00 [pubmed]
PHST- 1992/02/01 00:01 [medline]
PHST- 1992/02/01 00:00 [entrez]
AID - 10.1093/infdis/165.2.344 [doi]
PST - ppublish
SO  - J Infect Dis. 1992 Feb;165(2):344-51. doi: 10.1093/infdis/165.2.344.